Subjects with NAFLD used more often digitalis, diuretics, beta blocking agents, calcium channel blockers and inhibitors of angiotensin converting enzyme (ACE-inhibitors) compared to the subjects in the non-NAFLD group. This evidence concerns the gene ACE and metabolic dysfunction-associated steatotic liver disease.